Micro-Therapeutics launches new urological subsidiary:
This article was originally published in Clinica
Executive Summary
Micro-Therapeutics has formed a subsidiary to examine the possibilities for its Embolyx technology in urology and gynaecology. The new company, called Genyx Medical will be run by CEO Thomas Berryman, who is currently CFO of Micro-Therapeutics. Genyx will seek an initial round of financing. Micro-Therapeutics is backed by Guidant (see Clinica 784, p9). Embolyx is a biocompatible polymer dissolved in a solvent carrier, which rapidly precipitates as a solid in contact with body fluids. The new company plans to develop the product for urinary urge incontinence.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.